2 min read
Triangle Perspective on AI, ML, & the Future of Drug Development
Veristat Announces Participation in the "Triangle Perspective on AI, ML, & the Future of Drug Development" Panel...
1 min read
We are pleased to announce that our team has been selected as speakers at the plenary sessions:
Panel: "From early diagnosis to access to treatment for rare diseases - European and US perspectives"
Panel Summary: The panel will discuss the specifics of developing and bringing to market new innovative medicines for rare diseases and access to patients. Speakers will provide regulatory perspectives on orphan drugs in Europe and the U.S., market access considerations in Europe with a focus on Switzerland and explain the perspective and specifics of biotechnology in the development of highly innovative products.
Panel Date: 25th April from 14:30 to 15:15 CEST.
Panelists:
Anja Bührer, Vice President Regulatory Affairs and Deputy Head of SFL, a Veristat Company.
John Kirk, Senior Regulatory Strategist, Veristat
Anna Ulbricht, Senior Director Medical Affairs and Market Access, SFL a Veristat Company.
Charlotte Chanson, Senior Director Global Diagnostics/newborn Screening, Orchard Therapeutics
The panel will be moderated by Nathalie Schober-Ladani, Senior Director of Public Affairs and Regulatory Intelligence at SFL, a Veristat Company.
If you would like to meet us at The Swiss Biotech Day 2023, feel free to contact us to arrange a meeting through the form.
Website: https://swissbiotechday.ch/
2 min read
Jun 7, 2024 Veristat Events
Veristat Announces Participation in the "Triangle Perspective on AI, ML, & the Future of Drug Development" Panel...
2 min read
May 3, 2024 Veristat Events
Meet the Veristat team at ASCO, May 31st to June 4th in Chicago
The Science-First CRO™ and Consultancy Ready to...